Newsfeeds Archive - Spark Newswire

1 minute read

CRISPR Therapeutics’ Julianne Bruno, M.B.A., Promoted To COO, Effective May 23, 2024

May 23, 8:17 AM

-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A., promoted to Chief Operating Officer-ZUG, Switzerland and BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- CRISPR

CRSP

2 minute read

What’s Going On With Crispr Therapeutics Stock?

By Erica Kollmann

February 15, 12:36 PM

Crispr Therapeutics shares are trading higher Thursday after Wolfe Research analyst Andy Chen initiated coverage on Crispr Therapeutics with a Peer Perform rating. Crispr Therapeutics' shares have risen nearly 37% over the past month following the FDA approval of Casgevy (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older on Jan. 16.

CRSP

3 minute read

Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday

By Avi Kapoor

February 15, 11:23 AM

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

ALB

3 minute read

Check Out What Whales Are Doing With CRSP

By Benzinga Insights

February 14, 2:31 PM

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it’s something market players shouldn’t ignore.…

CRSP

1 minute read

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today

By Benzinga Insights

February 9, 12:00 PM

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 4.96% on an annualized basis…

CRSP

2 minute read

Jim Cramer Says It’s ‘Still Not Too Late’ To Buy This Energy Stock

By Avi Kapoor

January 31, 8:57 AM

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is taking a "hard pass" on Surgery Partners, Inc. (NASDAQ: SGRY). "That industry has been up and down and up and down," he added.

CRSP

2 minute read

Cathie Wood’s Ark Invest Sells $8.04M Worth of DraftKings Shares

By Benzinga Neuro

January 18, 12:09 AM

On Wednesday, Cathie Wood-led Ark Invest made a significant move by selling a substantial portion of its stake…

ARKG

2 minute read

FDA
News

Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex’s Casgevy Secures FDA Nod Ahead of Schedule

By Vandana Singh

January 17, 8:15 AM

FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the U.S.

BLUE